Mifepristone lawsuits update; new FOIA case

💬 Social Media Perspectives

On X, pro-life users like Lila Rose and Tony Perkins celebrate RFK Jr.'s FDA safety review of mifepristone, highlighting studies claiming 1 in 10 women face severe complications, a perspective emphasizing risks to women that mainstream coverage often downplays.
X posts from anti-abortion groups such as Americans United for Life share stories of mifepristone enabling abuse, like cases where men secretly administer the drug, adding context on exploitation risks absent in mainstream reports.
Pro-choice advocates on X, including ANSIRH and the EMAA Project, criticize the review as relying on 'junk science' and discredited studies, arguing it's a politically motivated attack on abortion access, which mainstream media covers less emphatically.
Discussions on X reference lawsuits claiming mifepristone harms states by lowering teen birth rates, leading to population decline and loss of federal funds, a demographic impact angle not prominently featured in mainstream outlets.
X users point to Twitter's 2025 demographics, with 586 million monthly active users mostly aged 25-34 and a male skew (around 56%), suggesting that younger, male-dominated conversations may amplify certain anti-abortion perspectives missing from broader media narratives.

Based on 2 sources

HHS Secretary Robert F. Kennedy Jr. ordered a new FDA review of mifepristone’s safety, citing a self‑published white paper funded by anti‑abortion groups as the basis for the review.
Americans United for Life and allied anti‑abortion groups criticized the FDA’s approval of a new generic mifepristone and helped produce and publicize the white paper that prompted the review.
Alliance Defending Freedom says it represents a Louisiana plaintiff in a medication‑abortion lawsuit against the FDA and expects the administration to appeal a recent court order in that case.
The ACLU filed a FOIA lawsuit on Nov. 13 seeking the parameters of the FDA’s new mifepristone review and the agency’s communications with outside groups about that review.
Together, the ordered FDA review, litigation from anti‑abortion groups, and the ACLU FOIA suit indicate escalating legal and public scrutiny over mifepristone’s approval and the FDA’s handling of its safety review.

Follow how coverage of this story developed over time

November 19, 2025

12:00 PM

Minnesota Reformer by Sofia Resnick

12:00 PM

Minnesota Reformer by Sofia Resnick

New information:

HHS Secretary Robert F. Kennedy Jr. ordered a new FDA review of mifepristone’s safety and cited a self‑published white paper funded by anti‑abortion groups as the basis.
Americans United for Life and allied groups criticized FDA’s approval of a new generic mifepristone and helped produce/publicize the white paper.
Alliance Defending Freedom says it represents a Louisiana plaintiff in a medication‑abortion case against FDA and expects the administration to appeal the recent court order.
The ACLU’s Nov. 13 FOIA lawsuit seeks the parameters of FDA’s new review and the agency’s communications with outside groups about it.